Elsevier

Toxicology

Volume 82, Issues 1–3, 5 October 1993, Pages 39-52
Toxicology

Recombinant yeast in drug metabolism

https://doi.org/10.1016/0300-483X(93)90058-ZGet rights and content

Abstract

The usefulness of cDNA-directed expression of human hepatic P450s in yeast for the in vitro study of drug metabolism is emphasized. The major advantages of yeast expression are: (i) relatively high yields of heterologous P450 (≈5–10 nmol/l of culture medium) can be obtained; (ii) the expressed P450s are directly active in yeast microsomes, allowing the determination of specific catalytic activities of individual isoforms, which is a prerequisite for the prediction of metabolic pathways for new drug candidates; (iii) transformed yeast microsomes can also be used to study the specific affinity of individual P450s for various substrates and the formation of P450-metabolite complexes by difference visible spectroscopy; such studies can help to predict drug interactions. The advantages of expression in yeast with respect to biochemical studies of drug metabolism are illustrated with data about P450 NF25 (P450 3A4), the major form of human liver. Expressed P450 NF25 is obtained in a functionally active state, and some specific catalytic activities observed in liver microsomes could be reproduced directly with transformed yeast microsomes. The use of genomically modified yeast strains coexpressing human cytochrome b5 and/or overexpressing yeast P450-reductase allowed us to optimize these catalytic activities. In particular, this coexpression system was useful in the study of the in vitro formation of a P450 NF25 Fe(II)-RNO complex. Such inhibitory complexes have been implied in numerous drug interactions involving P450 3A4.

References (25)

  • M.R. Franklin

    The formation of a 455-nm complex during cytochrome P450-dependent N-hydroxyamphetamine metabolism

    Mol. Pharmacol.

    (1974)
  • F.J. Gonzalez

    Molecular biology of cytochrome P450

    Pharmacol. Rev.

    (1989)
  • Cited by (45)

    • Comparative functional characterization of a novel benzoate hydroxylase cytochrome P450 of Fusarium oxysporum

      2015, Enzyme and Microbial Technology
      Citation Excerpt :

      Upon spectral analysis of the yeast microsomes, it was evident that the eukaryotic gene was able to be well expressed in the active form without any gene modifications, and hence we proceeded to characterize the catalytic properties of FoCYP53A19 in the yeast system. The cytochrome P450 reductase from yeast is an efficient redox donor for transferring electrons to various heterologous eukaryotic CYPs [21–23]. To compare the significance of CPR over the catalytic efficiency of FoCYP53A19, the well reported yeast NADPH reductases from S. cerevisiae (ScCPR) and C. albicans (CaCPR) were employed [21,24].

    • Metabolism related toxicity of diclofenac in yeast as model system

      2011, Toxicology Letters
      Citation Excerpt :

      Advantages of yeast over mammalian cell systems are its easy manipulation, cost-effectiveness, and rapid growth. Because wild type yeast strains lack drug-metabolizing cytochrome P450s and glucuronosyl-transferases, many biotransformation enzymes have been heterologously expressed in yeast (Pompon et al., 1997; Renaud et al., 1993). Expression of mammalian P450s in yeast has been used to investigate the mutagenic effects of oxidative metabolites of xenobiotics, as has been described for N-alkylformamides and aflatoxine B1 (Del Carratore et al., 2000; Guo et al., 2005).

    View all citing articles on Scopus
    View full text